Seminal vesicles

Mercy BioAnalytics Raises $41 Million in Series A Financing to Advance Novel Mercy Halo Liquid Biopsy Platform for Early Cancer Detection

Retrieved on: 
Monday, April 3, 2023
Science, Biotechnology, Research, Oncology, General Health, Health, Clinical Trials, Other Health, DNA, AACR, International Society for Extracellular Vesicles, Serum, Survival, American Society of Clinical Oncology, Cancer, Lung cancer, Doctor of Philosophy, II, Novalis, ASCO, Plasma, Seminal vesicles, ISEV, American Association for Cancer Research, Data, Mercy, American Cancer Society, Ovarian cancer, Labcorp, Society, Conference, International Society, Biopsy, Vaccine, Medical imaging, Bruker

Mercy BioAnalytics, Inc. , a pioneer in extracellular vesicle-based liquid biopsies for the early detection of cancer, today announced it has closed a $41 million Series A financing round.

Key Points: 
  • Mercy BioAnalytics, Inc. , a pioneer in extracellular vesicle-based liquid biopsies for the early detection of cancer, today announced it has closed a $41 million Series A financing round.
  • The company’s novel Mercy Halo™ platform unlocks high clinical sensitivity and specificity through the simultaneous detection of multiple cancer-related biomarkers co-localized on the surface of individual tumor-derived extracellular vesicles.
  • Proceeds from the financing will be used to advance development and commercialization of the Mercy Halo test for high-risk lung cancer screening, the company’s lead clinical indication.
  • Mercy intends to leverage its Mercy Halo liquid biopsy platform technology to develop a broad portfolio of tests for the early detection of cancer.

Direct Biologics Announces First Patient Dosed with ExoFlo™ in a Phase 1 Clinical Trial for Medically Refractory Ulcerative Colitis

Retrieved on: 
Tuesday, March 28, 2023
Health, Stem Cells, Clinical Trials, Research, Science, Biotechnology, Ulcerative colitis, Trial of the century, Regenerative medicine, EVS, Inflammatory bowel disease, Diagnosis, Ageing, C-reactive protein, Seminal vesicles, UC, Patient, Safety, Microsoft Exchange Server, Pharmaceutical industry

“The initiation of our ulcerative colitis clinical study is an important milestone as it marks the beginning of Direct Biologics’ clinical trial program for inflammatory bowel disease, a chronic condition with no known cure,” said Amy Lightner, Chief Medical Officer of Direct Biologics.

Key Points: 
  • “The initiation of our ulcerative colitis clinical study is an important milestone as it marks the beginning of Direct Biologics’ clinical trial program for inflammatory bowel disease, a chronic condition with no known cure,” said Amy Lightner, Chief Medical Officer of Direct Biologics.
  • “ExoFlo’s safety profile, combined with its anti-inflammatory, immunomodulatory and regenerative properties, make it an ideal next generation candidate for ulcerative colitis.
  • The primary objective for this trial is to evaluate the safety of intravenous ExoFlo in patients with moderate to severe UC.
  • The secondary objective is to evaluate the efficacy of intravenous ExoFlo in inducing clinical remission, clinical response, and improvement in patient reported outcomes.

ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 2022

Retrieved on: 
Wednesday, March 22, 2023
Pancreatic cancer, ALL, Pherecydes, EGM, Infection, Sale, Seminal vesicles, Patient, Phage therapy, Catalent, FDA, BLA, Pharmaceutical industry, TNBC

Cambridge, MA (U.S.) and Lyon (France), March 22, 2023 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today provided a business and financial update for the fourth quarter and full year of 2022.

Key Points: 
  • Cambridge, MA (U.S.) and Lyon (France), March 22, 2023 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today provided a business and financial update for the fourth quarter and full year of 2022.
  • We sold our US manufacturing site, sharply reduced our cash burn, focused on our most promising preclinical programs, and relentlessly pursued partnering options”, said Gil Beyen, Chief Executive Officer of ERYTECH.
  • Linked to the halt of the Company’s lead program Graspa®, a restructuring program was initiated in May 2022.
  • Key financial figures for the twelve months of 2022 compared with the same period of the previous year are summarized below:

Direct Biologics Announces Initiation of Phase 1 Clinical Trial for Medically Refractory Crohn’s Disease

Retrieved on: 
Tuesday, March 21, 2023
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Regenerative medicine, EVS, Inflammatory bowel disease, Clinical trial, Microsoft Exchange Server, C-reactive protein, Seminal vesicles, Patient, Safety, Pharmaceutical industry

Direct Biologics, LLC, a late-stage biotechnology company leveraging its regenerative medicine platform using extracellular vesicles (EVs) derived from bone marrow mesenchymal stem cells (MSCs) to address multiple disease indications, announced it has dosed the first patient in its Phase 1 clinical trial evaluating ExoFlo™ for the treatment of patients with medically refractory Crohn’s disease.

Key Points: 
  • Direct Biologics, LLC, a late-stage biotechnology company leveraging its regenerative medicine platform using extracellular vesicles (EVs) derived from bone marrow mesenchymal stem cells (MSCs) to address multiple disease indications, announced it has dosed the first patient in its Phase 1 clinical trial evaluating ExoFlo™ for the treatment of patients with medically refractory Crohn’s disease.
  • “We are excited to announce the initiation of our Crohn’s disease clinical trial as we expand our ExoFlo clinical development program into inflammatory bowel disease,” said Amy Lightner, M.D., Chief Medical Officer of Direct Biologics.
  • “Crohn’s disease is a debilitating lifelong condition that affects every aspect of daily life.
  • The secondary objective is to evaluate the efficacy of intravenous ExoFlo in inducing clinical response, clinical and endoscopic remission, and improving disease-specific, health-related quality of life.

Innovations in Flow Cytometry 2023 (Washington, United States - May 4-5, 2023) - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 15, 2023
Research, Science, Ribonucleotide, Colon, College of Engineering Chengannur, Analysis, Personalized medicine, EV, College, University of Washington, Cell, Nanostructure, Travel, University of California, Los Angeles, Protein, Biology, Exhibition, Architecture, Microfluidics, Bacteria, University, Seminal vesicles, MPS, Oligonucleotide, Physiology, Disease, Growth, Bioreactor, Peptide, Flow cytometry, Ecological niche, Biological engineering, University of Kansas, Medical imaging, Management, Medicine, Professor, Chemistry, Engineering

The second flow instrument is a digital flow cytometer, capable of high-sensitivity analysis of individual extracellular vesicles and particles.

Key Points: 
  • The second flow instrument is a digital flow cytometer, capable of high-sensitivity analysis of individual extracellular vesicles and particles.
  • I will discuss the platforms we are developing to perform quantum assays using standard flow cytometers and fluorescence activated cell sorters.
  • This presentation will describe transitioning of microfluidic organs-on-a-chip system to mesoscale systems compatible with automated flow cytometry.
  • Measurements using flow cytometry and imaging flow cytometry corroborated an association between levels of IgG secretion and CD138 expression.

Direct Biologics Reports Compelling Results From Phase 2 Trial With ExoFlo™ in Hospitalized Patients With Respiratory Failure or Moderate-to-Severe Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19

Retrieved on: 
Tuesday, March 14, 2023
COVID-19, Research, Clinical Trials, Stem Cells, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Trial of the century, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Șaeș, Respiratory failure, Ageing, Acute respiratory distress syndrome, Regenerative medicine, Aes, Seminal vesicles, Bone marrow, Disease, VFD, Patient, Death, MSC, Food, Perioperative, Microsoft Exchange Server, Incidence, EVS, FDA, DSMB, Multisite cloud, Mortality, Survival, Hospital, Pharmaceutical industry

“We are pleased to report compelling findings that provide hope to the thousands of patients around the world with respiratory failure and moderate-to-severe ARDS due to COVID-19.

Key Points: 
  • “We are pleased to report compelling findings that provide hope to the thousands of patients around the world with respiratory failure and moderate-to-severe ARDS due to COVID-19.
  • Findings demonstrated a significant survival benefit in ExoFlo-treated patients with respiratory failure due to COVID-19.
  • The FDA has granted Direct Biologics an allowance to proceed with a Phase 3 trial of ExoFlo-15 mL compared with placebo, randomized 1:1.
  • This multisite global trial will look at 60-day all-cause mortality in patients who meet Berlin criteria for moderate-to-severe ARDS.

Vesigen Therapeutics Awarded Grant from Friedreich’s Ataxia Research Alliance (FARA) to Develop a Targeted Genome Editing Therapeutic Strategy

Retrieved on: 
Tuesday, March 14, 2023
Biotechnology, Health, Genetics, Science, Research, Tissue, Friedreich's ataxia, FARA, DSM-IV codes, Doctor of Philosophy, Neuron, CRISPR, Neurodegenerative disease, Genome, Genetic disorder, Seminal vesicles, Patient, Multimedia, Engineering, Therapy, Drug development, ARMM (Usenet), FA, Vaccine, Pharmaceutical industry, Frataxin

Vesigen will evaluate its proprietary technology to deliver CRISPR-Cas genome editing complexes as a non-viral disease-modifying strategy for patients diagnosed with the neurodegenerative disease Friedreich's Ataxia (FA).

Key Points: 
  • Vesigen will evaluate its proprietary technology to deliver CRISPR-Cas genome editing complexes as a non-viral disease-modifying strategy for patients diagnosed with the neurodegenerative disease Friedreich's Ataxia (FA).
  • The FARA Grant Program funds competitive grants across the spectrum from basic research through drug development and clinical research programs.
  • “The work being done by Vesigen Therapeutics has the potential to be transformative for FA patients,” says Jennifer Farmer, CEO of FARA.
  • “We are grateful for Dr. Nabhan and his team for their work on this targeted genome editing strategy.”
    This is the first grant in neurological disorders received by Vesigen Therapeutics.

Global Exosomes Market Report 2023: Sector to Reach $1.03 Billion by 2030 at a CAGR 37.75% - ResearchAndMarkets.com

Retrieved on: 
Monday, March 6, 2023
Health, Biotechnology, Fluid mechanics, World Health Organization, CVD, Exosome, Therapy, Vaccine, Incidence, Prevalence, Cell, Research, Workflow, Biomarker, Growth, Death, USD, Pathogen, Patient, Cancer, COVID-19, Government, Investment, RNA, WHO, Seminal vesicles, Prognosis, Pharmaceutical industry, Medical imaging

Exosomes released by cells into body fluids display different RNA, protein, and lipid contents in patients with various disease conditions as compared to healthy individuals.

Key Points: 
  • Exosomes released by cells into body fluids display different RNA, protein, and lipid contents in patients with various disease conditions as compared to healthy individuals.
  • Hence, exosomes can be used for the development of diagnostic procedures using biomarker identification.
  • The COVID-19 pandemic led to the disruption of clinical trials investigating the diagnostic and therapeutic potential of exosomes in 2020.
  • Moreover, growth in government and non-government initiatives for exosome research is likely to drive the growth during the study period.

Biopsy Devices Market Predicted to Achieve Striking Growth of USD 3.96 Billion with Healthy CAGR of 7.3% by 2029, Size, Share, Trends, Demand and Competitive Analysis

Retrieved on: 
Tuesday, March 7, 2023
Sentinel, Laparoscopy, Diagnosis, Needle, Laboratory, DNA, Lymph node, Infection, Liquid biopsy, Breast cancer, Jamshidi needle, Nucleic acid thermodynamics, Saliva, Skin cancer, Magnetic resonance, Ambulatory Surgery Center Association, EVS, Archives of Pathology & Laboratory Medicine, Consumables, Prostate, Research, Disposable product, Midsayap Diagnostic Center and Hospital, Cancer, Academic institution, Prostate cancer, Prostate biopsy, Recurrence, Neoplasm, System, Lung cancer, National Virus Reference Laboratory, MRI, Inflammation, Liver cancer, Wilford Hall Ambulatory Surgical Center, Skeletal muscle, Biomarker, Seminal vesicles, Fine-needle aspiration, Chinese, Stereotactic surgery, Medical imaging, Trans, Hospital, Biopsy, Hysterectomy, Disease, Human factors and ergonomics, Country, Hysteroscopy

To Check the Complete Table of contents, click here @ https://www.databridgemarketresearch.com/toc/?dbmr=global-biopsy-devices...

Key Points: 
  • To Check the Complete Table of contents, click here @ https://www.databridgemarketresearch.com/toc/?dbmr=global-biopsy-devices...
    North America Biopsy Devices Market , By Product (Needle-Based Biopsy Instruments, Procedure Trays, Localization Wires and other Products), Application (Breast Biopsy, Lung Biopsy, Colorectal Biopsy, Prostate Biopsy and Other Applications), Guidance Technique (Ultrasound-Guided Biopsy, Stereotactic-Guided Biopsy, MRI-Guided Biopsy and Other Guidance Techniques), End User (Hospitals, Academic and Research Institutes, Diagnostic and Imaging Centers), and Country (U.S., Canada, Mexico) https://www.databridgemarketresearch.com/reports/north-america-biopsy-de...
    Europe Biopsy Devices Market , By Product (Needle-Based Biopsy Instruments, Procedure Trays, Localization Wires and other Products), Application (Breast Biopsy, Lung Biopsy, Colorectal Biopsy, Prostate Biopsy and Other Applications), Guidance Technique (Ultrasound-Guided Biopsy, Stereotactic-Guided Biopsy, Mri-Guided Biopsy and Other Guidance Techniques), End User (Hospitals, Academic and Research Institutes, Diagnostic and Imaging Centers), and Country https://www.databridgemarketresearch.com/reports/europe-biopsy-devices-m...
    Asia-Pacific Biopsy Devices Market By Product (Needle-Based Biopsy Instruments, Procedure Trays, Localization Wires and Other Products), Guidance Technique (Ultrasound-Guided Biopsy, Stereotactic-Guided Biopsy, MRI-Guided Biopsy and Other Guidance Techniques), Application (Breast Biopsy, Lung Biopsy, Colorectal Biopsy, Prostate Biopsy and Other Applications), End User (Hospitals, Academic and Research Institutes, Diagnostic and Imaging Centres), Country https://www.databridgemarketresearch.com/reports/asia-pacific-biopsy-dev...
    Breast Biopsy Devices Market , By Product (Biopsy Needles, Biopsy Tables, Biopsy Wires, Guidance Systems, Others), Technique Type (Fine Needle Aspiration Biopsy, Core Needle Biopsy, Biopsy Markers, MRI-Guided Core Needle Biopsy, Surgical Biopsy, Wire Localization, Sentinel Node Biopsy), Guidance Technology (Fine Ultrasound-Guided, Mammography-Guided Magnetic Resonance, CT-Guided Biopsy, Other Image-Guided Breast Biopsy), End User (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Other) https://www.databridgemarketresearch.com/reports/global-breast-biopsy-de...
    North America Breast Biopsy Devices Market , By Product (Biopsy Needles, Biopsy Tables, Biopsy Wires, Guidance Systems and Others), Technique Type (Fine Needle Aspiration Biopsy, Core Needle Biopsy, Biopsy Markers, MRI-Guided Core Needle Biopsy, Surgical Biopsy, Wire Localization and Sentinel Node Biopsy), Guidance Technology (Fine Ultrasound-Guided, Mammography-Guided Magnetic Resonance, CT-Guided Biopsy and Other Image-Guided Breast Biopsy), End User (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers and Other), and Country (U.S., Canada, Mexico) https://www.databridgemarketresearch.com/reports/north-america-breast-bi...
    Europe Breast Biopsy Devices Market , By Product (Biopsy Needles, Guidance Systems, Biopsy Tables, Localization Wires, Assay Kits, Liquid Biopsy Instruments, Others), Type (Needle Breast Biopsy, Open Surgical Breast Biopsy, Liquid Breast Biopsy, Other Biomarkers), Guidance (Image-Guided Biopsy, Liquid Biopsy, Other Guidance Techniques), Application (Early Cancer Screening, Therapy Selection, Treatment Monitoring, Recurrence Monitoring), Country https://www.databridgemarketresearch.com/reports/europe-breast-biopsy-de...
    Asia-Pacific Breast Biopsy Devices Market , By Product (Biopsy Needles, Biopsy Tables, Biopsy Wires, Guidance Systems, Others), Technique Type (Fine Needle Aspiration Biopsy, Core Needle Biopsy, Biopsy Markers, MRI-Guided Core Needle Biopsy, Surgical Biopsy, Wire Localization, Sentinel Node Biopsy), Guidance Technology (Fine Ultrasound-Guided, Mammography-Guided Magnetic Resonance, CT-Guided Biopsy, Other Image-Guided Breast Biopsy), End User (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Other), Country https://www.databridgemarketresearch.com/reports/asia-pacific-breast-bio...
    Smart Biopsy Devices Market , By Application (Breast Cancer, Skin Cancer, Liver Cancer, Prostate Cancer, Others), Product (Needle-Based Biopsy Instruments, Procedure Trays, Localization Wires, Other Products), Guidance Technique (Ultrasound-Guided Biopsy, Stereotactic-Guided Biopsy, Magnetic Resonance Imaging-Guided Biopsy, Other Guidance Techniques), End User (Hospitals, Academic and Research Institutes, Diagnostic and Imaging Centers) Country https://www.databridgemarketresearch.com/reports/global-smart-biopsy-dev...
    Vacuum Assisted Biopsy Devices Market , By Product (Vacuum-assisted Biopsy Systems, Vacuum-assisted Biopsy Needles), Type (9-12G, 12G), Technique (Ultrasound-guided Biopsy, Stereotactic-guided Biopsy, MRI-guided Biopsy, Others), Applications (Breast Biopsy, Lung Biopsy, Colorectal Biopsy, Prostate Biopsy, and Others), End User (Hospitals, Academic and Research Institutes, Diagnostic and Imaging Centers, Others) https://www.databridgemarketresearch.com/reports/global-vacuum-assisted-...
    Endobronchial Ultrasound Biopsy Devices Market , By Product (Biopsy Forceps, Cytology Brushes, Biopsy Needles, Trans bronchial Aspiration Needles, Spray Catheters, Others), Application (Cancer Diagnosis, Infection Diagnosis, Others), Country https://www.databridgemarketresearch.com/reports/global-endobronchial-ul...
    Liquid Biopsy Market , By Sampling Type (Blood Sampling Liquid Biopsy, Urine Sampling Liquid Biopsy and Saliva and Other Tissue Fluids Sampling Liquid Biopsy), Products and Service (Assays Kits, Instruments and Services), Circulating Biomarker (Circulating Tumour Cells, Circulating Tumour DNA (CTDNA), Cell-Free DNA, Extracellular Vesicles (EVS) and Other Circulating Biomarkers), Clinical Application (Early Cancer Screening, Therapy Selection, Treatment Monitoring and Recurrence Monitoring), Application (Cancer Applications and Non-Cancer Applications), End User (Reference Laboratories, Hospitals and Physician Laboratories, Academic and Research Centres and Other End Users) https://www.databridgemarketresearch.com/reports/global-liquid-biopsy-ma...
    Breast Cancer Liquid Biopsy Market , By Product (Consumables, Kits), Circulating Biomarkers (Extracellular Vesicles (EVs), Cell-free DNA (cfDNA), ctRNA, Circulating Tumor Cells (CTCs), cfRNA, Others), End Users (Laboratories, Hospitals, Physician Laboratories, Reference Laboratories, Public Health Laboratories, Research Institutes, Small Molecular Laboratories, Pathology Laboratories), Country https://www.databridgemarketresearch.com/reports/global-breast-cancer-li...
    Core Needle Biopsy Market , By Type (Full-Automated Core Needle Biopsy Device and Semi-Automated Core Needle Biopsy Device), Applications (Hospitals, Clinics and Others), Disease (Lung Cancer, Liver Cancer, Breast Cancer and Prostate Cancer), Range (14G- 18G, 18G), Distribution Channel (Direct Sales and Distributor), Country https://www.databridgemarketresearch.com/reports/global-core-needle-biop...
    Image-Guided Biopsy Market , By Technology (X- Ray, Ultrasound, Mammograpy, CT, MRI), Process (Fine Needle, Core Needle, Vacuum- Assisted Biopsy), End-User (Hospitals, Ambulatory Surgery Centers, Clinics, Research and Academic Institutes), Country https://www.databridgemarketresearch.com/reports/global-image-guided-bio...
    Vacuum-Assisted Biopsy Market By Guiding Technique (Stereotactic Vacuum Assist Biopsy System and Image Guided Vacuum Assist Biopsy System), Type (9-12G, 12G), Applications (Hospitals, Academic and Research Institutes and Diagnostics and Imaging Centres), Country https://www.databridgemarketresearch.com/reports/global-vacuum-assisted-...
    Needle Biopsy Market , By Needle Type (Trephine Biopsy Needles, Klima Sternal Needle, Salah Needle Aspiration Needle, Jamshidi Needle and Others), Ergonomics (Sharp, Blunt, Quincke, Chiba, Franseen and Others), Procedure (Fine-Needle Aspiration Biopsy, Core Needle Biopsy, Vacuum-Assisted Biopsy, Image-Guided Biopsy), Sample Site (Muscles, Bones and Other Organs), Utility (Disposable and Reusable), Application (Tumour, Infection, Inflammation and Others), End User (Hospitals, Diagnostic Centres, Biopsy Labs, Ambulatory Surgical Centres, Academic and Research Organizations and Others), Distribution Channel (Direct Tender, Retail Sales), Country https://www.databridgemarketresearch.com/reports/global-needle-biopsy-ma...
    Biopsy Forceps Market , By Type (Rigid Biopsy Forceps, Flexible Biopsy Forceps), Product Type (Cupped Jaws Biopsy Forceps, Oval Ring Jaws Biopsy Forceps, Radial Jaw Biopsy Forceps, Others), Usability (Disposable Biopsy Forceps, Reusable Biopsy Forceps), Application (Laparoscopy, Hysterectomy, Hysteroscopy, Others), End User (Hospitals, Clinics, Ambulatory Surgery Centers, Others), Country https://www.databridgemarketresearch.com/reports/global-biopsy-forceps-m...
    Biopsy Guns and Needles Market , By Product Type (Disposable, Reusable), Technique (Ultrasound-Guided Biopsy, Stereotactic-Guided Biopsy, MRI-Guided Biopsy, Others), Application (Breast Biopsy, Lung Biopsy, Colorectal Biopsy, Prostate Biopsy, Others), End User (Hospitals, Academic and Research Institutes, Diagnostic and Imaging Centers, Others), Country https://www.databridgemarketresearch.com/reports/global-biopsy-guns-and-...

Direct Biologics Appoints Dr. Amy Lightner as Chief Medical Officer

Retrieved on: 
Wednesday, February 15, 2023
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Disease, Regenerative medicine, Medical director, Mayo Clinic, Inflammatory Bowel Diseases, University of California, Los Angeles, Inflammatory bowel disease, Medicine, British Journal of Surgery, Patient, Entrepreneurship, Inflammation, Seminal vesicles, ASCRS, University, Colitis, MSC, American Board of Colon and Rectal Surgery, Stanford University, EVS, Cleveland Clinic, National Center for Regenerative Medicine, FDA, Translation, Society, Microsoft Exchange Server, California Institute for Regenerative Medicine, Pharmaceutical industry, Rectum

Direct Biologics, LLC, a late-stage biotechnology company leveraging its regenerative medicine platform using extracellular vesicles (EVs) derived from bone marrow mesenchymal stem cells (MSCs), announces the appointment of Amy Lightner, M.D.

Key Points: 
  • Direct Biologics, LLC, a late-stage biotechnology company leveraging its regenerative medicine platform using extracellular vesicles (EVs) derived from bone marrow mesenchymal stem cells (MSCs), announces the appointment of Amy Lightner, M.D.
  • In this role, Dr. Lightner will be responsible for the company’s clinical and medical affairs operations.
  • With her significant medical and clinical experience, coupled with her substantial understanding of MSC science, we believe Dr. Lightner will contribute substantially to Direct Biologics as we advance our lead product candidate ExoFlo through clinical development,” said Mark Adams, Co-Founder and Chief Executive Officer of Direct Biologics.
  • I witnessed firsthand ExoFlo’s positive medical effects among very sick patients with no other treatment options,” stated Dr. Lightner.